Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 73
- Registration Number
- NCT03530995
- Locations
- 🇬🇧
Quotient Sciences Ltd, Ruddington, Nottingham, United Kingdom
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2022-04-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03486314
- Locations
- 🇺🇸
Greenville Health System - Institute for Translational Oncology Research, Greenville, South Carolina, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 230
- Registration Number
- NCT03478033
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University College, London
- Target Recruit Count
- 675
- Registration Number
- NCT03474198
- Locations
- 🇮🇩
Saiful Anwar Hospital, Malang, Indonesia
🇺🇬Joint Clinical Research Centre, Mbarara, Uganda
🇺🇬Infectious Diseases Institute, Kampala, Uganda
Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 68
- Registration Number
- NCT03353857
- Locations
- 🇩🇪
CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany
🇩🇪CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 53
- Registration Number
- NCT03346837
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122
- Conditions
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 81
- Registration Number
- NCT03340662
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma
- Conditions
- Interventions
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT03326050
- Locations
- 🇪🇬
Asmaa Ahmed, Assiut, Egypt
Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT03311841
- Locations
- 🇺🇸
Clinical Pharmacology of Miami ( Site 0001), Hialeah, Florida, United States
🇺🇸Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States
This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men
- Conditions
- Interventions
- First Posted Date
- 2017-10-11
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 45
- Registration Number
- NCT03307252
- Locations
- 🇩🇪
CTC North GmbH & Co. KG, Hamburg, Hamburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.